Research programme: cell based inflammatory bowel disease therapeutics: Icahn School of Medicine/Takeda/University of Chicago

Drug Profile

Research programme: cell based inflammatory bowel disease therapeutics: Icahn School of Medicine/Takeda/University of Chicago

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator Icahn School of Medicine at Mount Sinai; Takeda Pharmaceuticals USA; University of Chicago
  • Class Cell therapies
  • Mechanism of Action Immunomodulators; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Inflammatory bowel diseases

Most Recent Events

  • 31 Mar 2016 Early research in Inflammatory bowel disease in USA (unspecified route)
  • 31 Mar 2016 Takeda Pharmaceuticals, Icahn School of Medicine at Mount Sinai and University of Chicago agree to co-develop cell based inflammatory bowel therapeutics in USA for Inflammatory bowel disaese
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top